MERRIMACK PHARMACEUTICALS INC Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2010 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Merrimack Pharmaceuticals Inc quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2010 to Q4 2023.
  • Merrimack Pharmaceuticals Inc Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $250M, a 0.11% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $250M +$279K +0.11% Dec 31, 2023 10-K 2024-03-07
Q4 2022 $250M +$275K +0.11% Dec 31, 2022 10-K 2024-03-07
Q4 2021 $250M +$681K +0.27% Dec 31, 2021 10-K 2024-03-07
Q4 2020 $249M +$1.78M +0.72% Dec 31, 2020 10-K 2023-03-09
Q4 2019 $247M -$1.01M -0.41% Dec 31, 2019 10-K 2022-03-09
Q4 2018 $248M +$12.4M +5.26% Dec 31, 2018 10-K 2021-03-10
Q4 2017 $236M -$178M -43.1% Dec 31, 2017 10-K 2020-03-12
Q4 2016 $415M +$88M +26.9% Dec 31, 2016 10-K 2019-03-06
Q4 2015 $327M +$69.1M +26.8% Dec 31, 2015 10-K 2018-03-12
Q4 2014 $257M +$50.2M +24.2% Dec 31, 2014 10-K 2018-03-12
Q4 2013 $207M +$37.7M +22.2% Dec 31, 2013 8-K 2017-12-15
Q4 2012 $170M +$37M +27.9% Dec 31, 2012 10-K 2016-02-26
Q4 2011 $133M +$28.8M +27.7% Dec 31, 2011 10-K 2015-02-27
Q4 2010 $104M Dec 31, 2010 10-K 2014-03-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.